A Study to Investigate the Safety and Immunogenicity of the SF2a-TT15 Synthetic Carbohydrate-based Conjugate Vaccine Against Shigella Flexneri 2a (GlycoShig3)

A Phase 2a Age Descending Study to Investigate the Safety and Immunogenicity of the SF2a-TT15 Synthetic Carbohydrate-based Conjugate Vaccine Against Shigella Flexneri 2a in Adults, Children, and Infant Target Population in Endemic Countries.

A study among adults, children and infants in Kenya to determine if a new type of glycoconjugate vaccine incorporating a synthetic carbohydrate component is safe and induces immunity against Shigella.

Study Overview

• Status: Completed
• Conditions: Healthy
• Intervention / Treatment: Biological: Injection SF2A-TT15 10 µg Adjuvanted; Biological: Injection Adjuvanted Placebo; Biological: Injection SF2A-TT15 2 µg; Biological: Injection Placebo; Biological: Injection SF2A-TT15 2 µg Adjuvanted; Biological: Injection SF2A-TT15 10 µg

Detailed Description

The purpose of this study is to examine the safety and immunogenicity of two doses of the parenteral synthetic carbohydrate-based conjugate vaccine against Shigella flexneri 2a (Shigella flexneri 2a-Tetanus Toxoid15 (SF2a-TT15)) adjuvanted or not with Alhydrogel in infants in an endemic country (Kenya), the target population for the vaccine, using an age-descending approach. In total, 232 participants will be enrolled in the study: 16 adults (18-50 years-old), 16 children (2-5 years-old) and 200 infants (9 months-old +/ 1 mo).

The vaccine will be tested in adults first, then in children and eventually in infants in Kenya (where Shigella infection is present), based on the safety/tolerability in each group before to moving to the other. Participants will be randomly assigned to receive the study vaccine or a placebo control (same solution but without the vaccine component). The participants will have to go through all the trial procedures including the 14 visits (3 injections and 11 follow-up) during a 16 months period.

• Study Type: Interventional
• Enrollment (Actual): 248
• Phase: Phase 2

Contacts and Locations

Study Locations

• Kenya
  • Kericho, Kenya
    • KEMRI / Henry M. Jackson Foundation Medical Research International

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 8 months to 50 years (Child, Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

For adults:

1. Healthy men and women between 18 and 50 (inclusive) years of age.
2. Subjects who provide written informed consent or thumb print in the presence of a witness to participate in the study
3. Women willing to use at least 1 reliable method of contraception during the study period, or are surgically sterilized, and agree to undergo repeated pregnancy tests (before each vaccination) and men willing to use an effective method of contraception (e.g. condom).

For children and infants:

1. Healthy boys and girls between 2 and 5 years of age for the children group (cohort 2)
2. Healthy boys and girls 9 mo-old (+/- 1 month) for the infant group (cohort 3)
3. Parents or legally acceptable representatives, as appropriate, who are willing and able to provide signed/thumb printed informed consent for children and infants.
4. Infant and children should have a normal nutritional Z score (-2 or greater) according to the mother and child health handbook of the republic of Kenya - Ministry of Health before entering the trial.

For all:

1. Signed/thumb written informed consent, in accordance with local practice, provided by adult volunteers (participants 18 years of age and older), parent(s) or legal representative(s) for children and infants participants as applicable, who, in the opinion of the Investigator, can and will comply with the requirements of the protocol.
2. Subjects in general good health in the opinion of the Investigator as determined by medical history, vital signs and a physical examination.
3. No clinically significant abnormalities in hematology, blood chemistry, or urinalysis laboratory tests at screening.
4. Negative HIV, Hepatitis B and Hepatitis C serology tests and malaria test.

Exclusion Criteria:

1. Subjects with a history of clinically significant gastrointestinal disorders (e.g. gastroesophageal reflux disease, peptic ulcer, celiac disease, inflammatory bowel disease).
2. Individuals with immunosuppressive diseases or under immunosuppressive therapy.
3. Previous participation in any study in which a Shigella-vaccine candidate was administered.
4. Suspected or known hypersensitivity (including allergy) to any of the vaccine components or to previous vaccine, or to medicinal products or medical equipment whose use is foreseen in this study.
5. Use of any prescription or over-the-counter (OTC) medications, within 14 days prior vaccination. Paracetamol or ibuprofen for symptomatic relief of pain is allowed until 48 hours prior to vaccination.
6. Women who are pregnant, breast-feeding, or are of childbearing age and are not on or do not plan to use acceptable contraceptives for the duration of the study.
7. Subjects with any significant acute medical situation (e.g. acute infection) within 48 hrs prior to study entry, in the opinion of the Principal Investigator.
8. Participation in another clinical trial with drugs within 3 months prior first study injection.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

12

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Adults cohort 1 vaccinees; Eligible subjects (adults - 18 to 50 yr-old) will be randomized to receive 3 intramuscular (IM) injections with the 10μg OS adjuvanted dose (or matching placebo), at a ratio of 3:1.	Biological: Injection SF2A-TT15 10 µg Adjuvanted; Intramuscular injection of experimental vaccine (adjuvanted 10 µg); Other Names: SF2A-TT15 10 µg Adjuvanted; Anti-shigella experimental vaccine (10µg with alhydrogel)
Placebo Comparator: Adults cohort 1 placebo recipients; Eligible subjects (adults - 18 to 50 yr-old) will be randomized to receive 3 IM injections with the adjuvanted matching placebo.	Biological: Injection Adjuvanted Placebo; Intramuscular injection of Placebo with alhydrogel; Other Names: Placebo with Alhydrogel injection
Experimental: Children cohort 2 vaccinees; Eligible subjects (Children 2 to 5 yr-old) will be randomized to receive 3 IM injections of the 10 μg OS dose with Alhydrogel (or matching placebo) at a ratio of 3:1.	Biological: Injection SF2A-TT15 10 µg Adjuvanted; Intramuscular injection of experimental vaccine (adjuvanted 10 µg); Other Names: SF2A-TT15 10 µg Adjuvanted; Anti-shigella experimental vaccine (10µg with alhydrogel)
Placebo Comparator: Children cohort 2 placebo recipients; Eligible subjects (Children 2 to 5 yr-old) will be randomized to receive 3 IM injections of the matching placebo with Alhydrogel.	Biological: Injection Adjuvanted Placebo; Intramuscular injection of Placebo with alhydrogel; Other Names: Placebo with Alhydrogel injection
Experimental: Infants cohort 3A vaccinees (-); Eligible subjects (9 mo-old +/- 1mo infants) will be randomized to receive 3 IM injections of the not adjuvanted 2 μg dose (or of matching placebo), at a ratio of 4:1.	Biological: Injection SF2A-TT15 2 µg; Intramuscular injection of experimental vaccine (not adjuvanted 2 µg); Other Names: SF2A-TT15 2 µg not adjuvanted; Anti-shigella experimental vaccine (2µg without alhydrogel)
Placebo Comparator: Infants cohort 3A placebo recipients (-); Eligible subjects (9 mo-old +/- 1mo infants) will be randomized to receive 3 IM injections of the not adjuvanted matching placebo.	Biological: Injection Placebo; Intramuscular injection of the not adjuvanted Placebo; Other Names: Placebo without alhydrogel injection
Experimental: Infants cohort 3A vaccinees (+); Eligible subjects (9 mo-old +/- 1mo infants) will be randomized to receive 3 IM injections of the adjuvanted 2 μg dose (or of matching placebo), at a ratio of 4:1.	Biological: Injection SF2A-TT15 2 µg Adjuvanted; Intramuscular injection of experimental vaccine (adjuvanted 2 µg); Other Names: SF2A-TT15 2 µg Adjuvanted; Anti-shigella experimental vaccine (2µg with alhydrogel)
Placebo Comparator: Infants cohort 3A placebo recipients (+); Eligible subjects (9 mo-old +/- 1mo infants) will be randomized to receive 3 IM injections of the adjuvanted matching placebo.	Biological: Injection Adjuvanted Placebo; Intramuscular injection of Placebo with alhydrogel; Other Names: Placebo with Alhydrogel injection
Experimental: Infants cohort 3B vaccinees (-); Eligible subjects (9 mo-old +/- 1mo infants) will be randomized to receive 3 IM injections of the not adjuvanted 10 μg dose (or of matching placebo), at a ratio of 4:1.	Biological: Injection SF2A-TT15 10 µg; Intramuscular injection of experimental vaccine (not adjuvanted 10 µg); Other Names: SF2A-TT15 10 µg not adjuvanted; Anti-shigella experimental vaccine (10µg without alhydrogel)
Placebo Comparator: Infants cohort 3B placebo recipients (-); Eligible subjects (9 mo-old +/- 1mo infants) will be randomized to receive 3 IM injections of the not adjuvanted matching placebo.	Biological: Injection Placebo; Intramuscular injection of the not adjuvanted Placebo; Other Names: Placebo without alhydrogel injection
Experimental: Infants cohort 3B vaccinees (+); Eligible subjects (9 mo-old +/- 1mo infants) will be randomized to receive 3 IM injections of the adjuvanted 10 μg dose (or of matching placebo), at a ratio of 4:1.	Biological: Injection SF2A-TT15 10 µg Adjuvanted; Intramuscular injection of experimental vaccine (adjuvanted 10 µg); Other Names: SF2A-TT15 10 µg Adjuvanted; Anti-shigella experimental vaccine (10µg with alhydrogel)
Placebo Comparator: Infants cohort 3B placebo recipients (+); Eligible subjects (9 mo-old +/- 1mo infants) will be randomized to receive 3 IM injections of the adjuvanted matching placebo.	Biological: Injection Adjuvanted Placebo; Intramuscular injection of Placebo with alhydrogel; Other Names: Placebo with Alhydrogel injection

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number, proportion,severity and relatedness of adverse events (AEs) to measure the safety and tolerability of SF2a-TT15 vaccine (2 μg OS and 10 μg OS) in each cohort.	Solicited reactions, AEs, SAEs assessed post-vaccination using targeted physical examinations, vital signs, and clinical laboratory tests	15 months
Analyses of the serum anti-S. flexneri 2a lipopolysaccharide (LPS) IgG antibody response in the infant target population to assess the immunogenicity of the vaccine.	Proportion of responders (4-fold increases over baseline) in serum anti-S. flexneri 2a LPS IgG antibody response	15 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The number and proportion of responders, the geometric mean titer (GMT), mean fold-rises (compared to baseline), and peak-post-vaccination of the serum bactericidal activity (SBA) antibody (functionality of SF2a-specific IgGs antibodies in infants).	Proportion of responders (4-fold increases over baseline) in serum bactericidal activity (SBA) antibody	15 months
Analyses of the serum anti-S. flexneri 2a LPS Immunoglobulins G (IgG) antibody response in the adult and children cohorts.	Proportion of responders (4-fold increases over baseline) in serum anti-S. flexneri 2a LPS IgG antibody response	15 months
Comparison of the Measle-Rubella (MR) vaccine immune response in SF2a-TT15 vaccinees and placebo groups for the infant cohort.	The antibody titer to the MR vaccine will be compared between SF2a-TT15 vaccinees and placebo groups to assess whether the SF2a-TT15 Shigella vaccine candidate impacts on the immunogenicity of the MR vaccine.	15 months

Collaborators and Investigators

• Sponsor: Institut Pasteur
• Collaborators: Wellcome Trust; Walter Reed Army Institute of Research (WRAIR); Parexel; Bill & Melinda Gates Medical Research Institute; Henry M. Jackson Foundation Medical Research International; ClinWin Research
• Investigators: Study Chair: Armelle Phalipon, PhD, Institut Pasteur; Study Chair: Laurence Mulard, PhD, Institut Pasteur; Principal Investigator: Fredrick Sawe, MBChB MMED, Kenya Medical Research Institute; Study Chair: Christiane Gerke, PhD, Institut Pasteur (Consulting)

Study record dates

Study Major Dates

• Study Start (Actual): October 6, 2020
• Primary Completion (Actual): April 12, 2023
• Study Completion (Actual): November 15, 2023

Study Registration Dates

• First Submitted: September 24, 2020
• First Submitted That Met QC Criteria: October 20, 2020
• First Posted (Actual): October 26, 2020

Study Record Updates

• Last Update Posted (Actual): April 23, 2024
• Last Update Submitted That Met QC Criteria: April 22, 2024
• Last Verified: April 1, 2024

More Information

Terms related to this study

• Keywords: vaccine; Kenya; anti-shigella; shigella; diarrheic disease
• Additional Relevant MeSH Terms: Digestive System Diseases; Infections; Gastrointestinal Diseases; Gastroenteritis; Intestinal Diseases; Gram-Negative Bacterial Infections; Bacterial Infections; Bacterial Infections and Mycoses; Enterobacteriaceae Infections; Dysentery; Dysentery, Bacillary; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Immunologic Factors; Gastrointestinal Agents; Adjuvants, Immunologic; Antacids; Vaccines; Aluminum Hydroxide
• Other Study ID Numbers: 2018-017

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: This study is a part of a development program, Data will stay confidential and possibly shared only with program partners.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No